Sign Up to like & get recommendations! 2
Published in 2021 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2021.19741
Abstract: This cohort study examines antibody responses in infection-naive and previously infected individuals after 1 and 2 doses of the BNT162b2 vaccine. read more here.
Sign Up to like & get recommendations! 0
Published in 2020 at "JAMA ophthalmology"
DOI: 10.1001/jamaophthalmol.2020.3962
Abstract: Importance Coronavirus disease 2019 (COVID-19) has been recognized as a pandemic by the World Health Organization. Whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can also infect tissues besides the respiratory system, such as the… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Journal of Clinical Immunology"
DOI: 10.1007/s10875-022-01251-3
Abstract: We read with great interest the article by Ane F Salinas et al. [1] concerning early immune responses after BNT162b2 immunization in a cohort of 41 SARS-CoV-2 infectionnaïve or previously infected patients with common variable… read more here.
Sign Up to like & get recommendations! 1
Published in 2021 at "Clinical Microbiology and Infection"
DOI: 10.1016/j.cmi.2021.05.004
Abstract: Objectives Data on the immune response after two doses of BNT162b2 are so far limited. Previously infected individuals were excluded from pivotal clinical trials and the optimal dose regimen in this population has not been… read more here.
Sign Up to like & get recommendations! 2
Published in 2023 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofad161
Abstract: Abstract Background The protective efficacy of prior coronavirus disease 2019 (COVID-19) with or without vaccination remains unknown. This study sought to understand if 2 or more messenger RNA (mRNA) vaccine doses provide additional protection in… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Journal of Clinical Microbiology"
DOI: 10.1128/jcm.02390-21
Abstract: Emergency departments (EDs) can serve as surveillance sites for infectious diseases. The objective of this study was to determine the burden of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and to monitor the prevalence… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Journal of Virology"
DOI: 10.1128/jvi.01366-22
Abstract: The emergence of SARS-CoV-2 variants and the widespread use of COVID-19 vaccines has resulted in individual differences in immune status against SARS-CoV-2. A decay in immunity over time and the emergence of variants that partially… read more here.
Sign Up to like & get recommendations! 3
Published in 2022 at "Eurosurveillance"
DOI: 10.2807/1560-7917.es.2022.27.4.2101196
Abstract: Infections with the Omicron SARS-CoV-2 variant are rapidly increasing worldwide. Among 174,349 SARS-CoV-2-infected individuals (≥ 12 years), we observed an increased risk of S gene target failure, predictive of the Omicron variant, in vaccinated (odds ratio… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.876533
Abstract: Background Safe and effective vaccines against COVID-19 are critical for preventing the spread of SARS-CoV-2, but little is known about the humoral immune response more than 9 months after vaccination. We aimed to assess the… read more here.
Sign Up to like & get recommendations! 1
Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.953949
Abstract: Two doses of BNT162b2 mRNA vaccine induces a strong systemic SARS-CoV-2 specific humoral response. However, SARS-CoV-2 airborne transmission makes mucosal immune response a crucial first line of defense. Therefore, we characterized SARS-CoV-2-specific IgG responses induced… read more here.
Sign Up to like & get recommendations! 3
Published in 2023 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2023.1123158
Abstract: We examined the immune response in subjects previously infected with SARS-CoV2 and infection-naïve 9 months after primary 2-dose COVID-19 mRNA vaccination and 3 months after the booster dose in a longitudinal cohort of healthcare workers.… read more here.